Proposed Data Collections Submitted for Public Comment and Recommendations, 15187-15188 [06-2934]
Download as PDF
<![CDATA[
15187
Federal Register / Vol. 71, No. 58 / Monday, March 27, 2006 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–06–06AX]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Seleda Perryman,
CDC Assistant Reports Clearance
Officer, 1600 Clifton Road, MS–D74,
Atlanta, GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Risk Perception, Worry, and Use of
Ovarian Cancer Screening among
Women at High, Elevated, and Average
Risk of Ovarian Cancer—New—National
Center for Chronic Disease Prevention
and Health Promotion (NCCDPHP),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Accounting for an estimated 22,220
cases and 16,210 deaths in 2005,
ovarian cancer is the most frequent
cause of death from gynecologic
malignancy in the United States. In over
80 percent of patients, ovarian cancer
presents at a late clinical stage, affording
a five-year survival rate of only 35
percent. For cases where ovarian cancer
is identified in Stage I, however, the
five-year survival rate exceeds 90
percent.
Identifying a woman’s risk of ovarian
cancer plays a large role in determining
the appropriateness of having her
undergo screening. It is only for women
with a strong family history of ovarian
and/or breast cancer or women with a
hereditary genetic risk for ovarian
cancer that the currently available
screening modalities of CA 125 and
transvaginal ultrasound are
recommended.
Statements from the scientific and
medical community regarding
recommendations for ovarian cancer
screening play only a partial role in a
woman’s decision to undergo screening
exams. Numerous psychological and
sociological factors can affect this
decision as well, including a woman’s
knowledge, attitudes, beliefs, and
experiences. For instance, a woman’s
experience of cancer within her family
or experience with a friend who has had
cancer may influence a woman’s
screening decisions.
The literature also notes that women
with a family history of ovarian cancer
report increased worry and high levels
of perceived risk. A positive association
has also been shown between screening
behavior and family history. Recent
studies indicate, however, that
screening is not occurring in proportion
to women’s levels of risk. These
findings underscore the need for a better
understanding of how perceived risk of
ovarian cancer may influence worry
about cancer and ultimately screening
behavior.
To address these issues, the Division
of Cancer Prevention and Control
(DCPC), at the National Center for
Chronic Disease Prevention and Health
Promotion, Centers for Disease Control
and Prevention, is conducting a study to
examine the effects of family history of
cancer, knowledge about ovarian cancer,
worry and/or anxiety, and perceived
risk of cancer on the likelihood of a
woman undergoing screening for
ovarian cancer. By also examining other
psycho-social factors such as a woman’s
closeness to a relative or friend with
cancer, coping style, cancer worry, use
of other cancer screening tests, social
support, and provider’s
recommendations, the study will
elucidate the causal pathway leading
from actual risk (as measured by family
history) through perceived risk to intent
to undergo screening and actual
screening behavior.
The proposed study will consist of
two tasks:
Task 1, a brief eligibility screener (5
minutes) preceding a baseline survey
administered through a computerassisted telephone interview (CATI)
program. Approximately 2000 women
will be asked a series of questions over
a 35-minute time period. Questions will
cover key variables related to ovarian
cancer screening including coping,
anxiety, perceived risk, worry, personal
cancer history, family cancer history,
closeness with family or friends who
have had cancer, screening behavior,
and knowledge of ovarian cancer.
Task 2, a follow-up questionnaire will
be administered, also using a CATI
program, to approximately 1800 of the
women included in the baseline
questionnaire. Each of the women will
be contacted one year after they
complete the baseline survey. The
researchers anticipate a 10 percent
attrition of the sample between baseline
and follow-up. In the follow-up, women
will be asked a series of questions over
a 15-minute time period. The purpose of
this data collection effort is to determine
if risk perception has changed and to
ask about screening for ovarian cancer,
since the baseline questionnaire was
administered. All data will be collected
over a three-year time period. There are
no costs to respondents except their
time to participate in the survey.
ESTIMATED ANNUALIZED BURDEN TABLE
No. of
Respondents
wwhite on PROD1PC65 with NOTICES
Respondents
Average
burden per
response
(in hrs.)
No. of
Responses per
respondent
Total burden
(in hours)
Telephone Screener ................................................................................
Baseline Survey (women 30 or older) .....................................................
Follow-up Survey (completed Baseline Survey) .....................................
10667
667
600
1
1
1
5/60
35/60
15/60
889
389
150
Total ..................................................................................................
..........................
..........................
..........................
1428
VerDate Aug<31>2005
18:19 Mar 24, 2006
Jkt 208001
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
\\ALPHA3\E\FR\FM\27MRN1.SGM
27MRN1
15188
Federal Register / Vol. 71, No. 58 / Monday, March 27, 2006 / Notices
Dated: March 20, 2006.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 06–2934 Filed 3–24–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Decision to Evaluate a Petition to
Designate a Class of Employees at
Blockson Chemical Company, Joliet,
Illinois, To Be Included in the Special
Exposure Cohort
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
FOR FURTHER INFORMATION CONTACT:
Larry Elliott, Director, Office of
Compensation Analysis and Support,
National Institute for Occupational
Safety and Health, 4676 Columbia
Parkway, MS C–46, Cincinnati, OH
45226, Telephone 513–533–6800 (this is
not a toll-free number). Information
requests can also be submitted by e-mail
to OCAS@CDC.GOV.
Dated: March 21, 2006.
John Howard,
Director, National Institute for Occupational
Safety and Health Centers for Disease Control
and Prevention.
[FR Doc. E6–4388 Filed 3–24–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[FDA 225–06–8001]
The Department of Health and
Human Services (HHS) gives notice as
required by 42 CFR 83.12(e) of a
decision to evaluate a petition to
designate a class of employees at the
Blockson Chemical Company, in Joliet,
Illinois, to be included in the Special
Exposure Cohort under the Energy
Employees Occupational Illness
Compensation Program Act of 2000. The
initial proposed definition for the class
being evaluated, subject to revision as
warranted by the evaluation, is as
follows:
Facility: Blockson Chemical
Company.
Location: Building 55.
Job Titles and/or Job Duties: Utility
Engineer, Laborer, Research Chemist,
Relief Operator, Plant Operator,
Maintenance and Pipefitter, Lead Mixer,
Operator, and Supervisor HF Acid.
Period of Employment: October 10,
1952 through December 31, 1962.
wwhite on PROD1PC65 with NOTICES
SUMMARY:
VerDate Aug<31>2005
18:19 Mar 24, 2006
Jkt 208001
Memorandum of Understanding
Between the Food and Drug
Administration, Department of Health
and Human Services, of the United
States of America and the Certification
and Accreditation Administration of
the People’s Republic of China
Covering Ceramicware Intended for
Use in the Preparation, Serving or
Storage of Food or Drink and Offered
for Export to the United States of
America
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is providing
notice of a memorandum of
understanding (MOU) between the Food
and Drug Administration, Department of
Health and Human Services, of the
United States of America and the
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Certification and Accreditation
Administration of the People’s Republic
of China (CNCA).
The purpose of this MOU is to
establish a certification system that
increases the likelihood that daily-use
ceramicware manufactured in the
People’s Republic of China (China) and
offered for import into the United States
complies with U.S. law. To that end,
this MOU sets forth the criteria for
certification of ceramicware to be
exported directly from China to the
United States and intended for use in
the preparation, serving, or storage of
food, and for certification of firms in
China that are manufacturing such
ceramicware. These certifications will
enable FDA to reduce the frequency of
its sampling of daily-use ceramicware
from factories in China certified by
CNCA/China Entry-Exit Inspection and
Quarantine Bureaus (CIQs) and offered
for import into the United States, in
accordance with FDA’s confidence in
the effectiveness of the CNCA/CIQ
factory certification system.
DATES: The agreement became effective
January 26, 2006 (last signature date of
the Chinese version of the MOU).
FOR FURTHER INFORMATION CONTACT:
Matthew E. Eckel, Office of
International Programs (HFG–1), Food
and Drug Administration, 5600 Fishers
Lane, Rockville MD, 20857, 301–827–
4480, FAX: 301–480–0716.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 20.108(c),
which states that all written agreements
and understandings between FDA and
others shall be published in the Federal
Register, the agency is publishing notice
of this MOU.
Dated: March 17, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
BILLING CODE 4160–01–S
\\ALPHA3\E\FR\FM\27MRN1.SGM
27MRN1
]]>Agencies
[Federal Register Volume 71, Number 58 (Monday, March 27, 2006)]
[Notices]
[Pages 15187-15188]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-2934]
[[Page 15187]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-06-06AX]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-5960
and send comments to Seleda Perryman, CDC Assistant Reports Clearance
Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail
to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Risk Perception, Worry, and Use of Ovarian Cancer Screening among
Women at High, Elevated, and Average Risk of Ovarian Cancer--New--
National Center for Chronic Disease Prevention and Health Promotion
(NCCDPHP), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
Accounting for an estimated 22,220 cases and 16,210 deaths in 2005,
ovarian cancer is the most frequent cause of death from gynecologic
malignancy in the United States. In over 80 percent of patients,
ovarian cancer presents at a late clinical stage, affording a five-year
survival rate of only 35 percent. For cases where ovarian cancer is
identified in Stage I, however, the five-year survival rate exceeds 90
percent.
Identifying a woman's risk of ovarian cancer plays a large role in
determining the appropriateness of having her undergo screening. It is
only for women with a strong family history of ovarian and/or breast
cancer or women with a hereditary genetic risk for ovarian cancer that
the currently available screening modalities of CA 125 and transvaginal
ultrasound are recommended.
Statements from the scientific and medical community regarding
recommendations for ovarian cancer screening play only a partial role
in a woman's decision to undergo screening exams. Numerous
psychological and sociological factors can affect this decision as
well, including a woman's knowledge, attitudes, beliefs, and
experiences. For instance, a woman's experience of cancer within her
family or experience with a friend who has had cancer may influence a
woman's screening decisions.
The literature also notes that women with a family history of
ovarian cancer report increased worry and high levels of perceived
risk. A positive association has also been shown between screening
behavior and family history. Recent studies indicate, however, that
screening is not occurring in proportion to women's levels of risk.
These findings underscore the need for a better understanding of how
perceived risk of ovarian cancer may influence worry about cancer and
ultimately screening behavior.
To address these issues, the Division of Cancer Prevention and
Control (DCPC), at the National Center for Chronic Disease Prevention
and Health Promotion, Centers for Disease Control and Prevention, is
conducting a study to examine the effects of family history of cancer,
knowledge about ovarian cancer, worry and/or anxiety, and perceived
risk of cancer on the likelihood of a woman undergoing screening for
ovarian cancer. By also examining other psycho-social factors such as a
woman's closeness to a relative or friend with cancer, coping style,
cancer worry, use of other cancer screening tests, social support, and
provider's recommendations, the study will elucidate the causal pathway
leading from actual risk (as measured by family history) through
perceived risk to intent to undergo screening and actual screening
behavior.
The proposed study will consist of two tasks:
Task 1, a brief eligibility screener (5 minutes) preceding a
baseline survey administered through a computer-assisted telephone
interview (CATI) program. Approximately 2000 women will be asked a
series of questions over a 35-minute time period. Questions will cover
key variables related to ovarian cancer screening including coping,
anxiety, perceived risk, worry, personal cancer history, family cancer
history, closeness with family or friends who have had cancer,
screening behavior, and knowledge of ovarian cancer.
Task 2, a follow-up questionnaire will be administered, also using
a CATI program, to approximately 1800 of the women included in the
baseline questionnaire. Each of the women will be contacted one year
after they complete the baseline survey. The researchers anticipate a
10 percent attrition of the sample between baseline and follow-up. In
the follow-up, women will be asked a series of questions over a 15-
minute time period. The purpose of this data collection effort is to
determine if risk perception has changed and to ask about screening for
ovarian cancer, since the baseline questionnaire was administered. All
data will be collected over a three-year time period. There are no
costs to respondents except their time to participate in the survey.
Estimated Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
No. of Average burden
Respondents No. of Responses per per response Total burden
Respondents respondent (in hrs.) (in hours)
----------------------------------------------------------------------------------------------------------------
Telephone Screener.......................... 10667 1 5/60 889
Baseline Survey (women 30 or older)......... 667 1 35/60 389
Follow-up Survey (completed Baseline Survey) 600 1 15/60 150
-------------------------------------------------------------------
Total................................... ............... ............... ............... 1428
----------------------------------------------------------------------------------------------------------------
[[Page 15188]]
Dated: March 20, 2006.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. 06-2934 Filed 3-24-06; 8:45 am]
BILLING CODE 4163-18-P
